PTC 596

Drug Profile

PTC 596

Alternative Names: Bmi-1; PTC596

Latest Information Update: 08 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator PTC Therapeutics
  • Class Small molecules
  • Mechanism of Action BMI1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 Jul 2017 University of Oklahoma and PTC Therapeutics plan a phase I trial for Ovarian cancer (Neoadjuvant therapy, Late-stage disease; Newly diagnosed, First-line therapy) (NCT03206645)
  • 02 Jun 2017 Pharmacokinetics, efficacy and adverse events data from a first-in-human phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Nov 2016 PTC Therapeutics plans clinical trials for Solid tumours in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top